Drug
EDP-938 clinical trials
Also written EDP-938.
- studies test it
- 13
- open now
- 1
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the EDP-938 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- EDP-938
- 11
Other names
Studies by the year they started
13 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Moxifloxacin (1) · Tacrolimus (1) · Dabigatran (1) · Rosuvastatin (1) · Midazolam (1) · Fluconazole (1) · Itraconazole (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses EDP-938 is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial VirusRecruitingPhase 2Enanta Pharmaceuticals, IncNCT07482657Written as zelicapavir
- A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.CompletedPhase 2Enanta Pharmaceuticals, IncNCT05568706Written as EDP-938
- A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsCompletedPhase 1Enanta Pharmaceuticals, IncNCT06601192Written as zelicapavir (therapeutic dose)
- A Study to Evaluate EDP 938 Regimens in Children With RSVCompletedPhase 2Enanta Pharmaceuticals, IncNCT04816721Written as EDP-938
- Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractTerminatedPhase 2Enanta Pharmaceuticals, IncNCT04633187Written as EDP-938
- A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult SubjectsCompletedPhase 2Enanta Pharmaceuticals, IncNCT04196101Written as EDP-938
- A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelCompletedPhase 2Enanta Pharmaceuticals, IncNCT03691623Written as EDP-938 Dose 1
- Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT04927793Written as EDP-938
- Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT04498741Written as EDP-938
- Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT04871724Written as EDP-938
- Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03755778Written as EDP-938
- Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03750383Written as EDP-938
- A Study of EDP-938 in Healthy SubjectsCompletedPhase 1Enanta Pharmaceuticals, IncNCT03384823Written as EDP-938